Our fund have invested in a Life Science Tools company, S2 Genomics.
S2 Genomics is a Life Science tools company. The company has developed SingulatorTM using patented technology to automates preparation of single cell and nuclei suspensions from solid tissues on cartridges. The product has just been commercially released. With many back orders from various industrial clients, the company actually is expected to be profitable next year. This is pretty unusual for an only a couple of years old startup company.
The company has set a goal to disrupt the traditional production process of single cell preparation. Its Strategy is to win single cell genomics beachhead for processing solid tissues into single cells and nuclei.
Single cell sequencing is exploding:
Single cell genomics can reveal many aspects of cells. For example,
- Heterogeneity of cells and gene expression
- New cell types
- How tissues develop
- Cell interactions
- Drug resistance in cancers
As can be seen, single cell genomics is critically impacting clinical research and precision medicine today. In 2020, the single cell market is estimated at $2.7b. With such a huge market, however, 90% work are done manually to isolate single cells and nuclei from solid tissues. Therefore, preparing single cells or nuclei from solid tissues has become the bottleneck.
Sensing the needs, S2 Genomics has developed Singulator TM using patented technology to automates preparation of single cell and nuclei suspensions from solid tissues on cartridges. The product has just been commercially released this month. The company have back orders from various industrial clients. It is expected to be profitable next year.